Skip to main content
Retour
ORKA logo

Oruka Therapeutics, Inc.

Qualité des données : 100%
ORKA
NASDAQ Healthcare Biotechnology
39,90 €
▼ 1,66 € (-3,99%)
Cap. Boursière : 1,49B
Fourchette du Jour
39,09 € 40,78 €
Fourchette 52 Semaines
5,49 € 42,88 €
Volume
457 549
Moyenne 50J / 200J
34,01 € / 23,79 €
Clôture Précédente
41,56 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -14,2 0,3
P/B 3,2 2,9
ROE % -24,7 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
55,86 € +40.0%
Low: 40,00 € High: 75,00 €
BPA Prévisionnel
-2,36 €
CA Est.
0

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 -4,44 €
-4,44 € – -4,44 €
40 M 5
FY2029 -3,99 €
-3,99 € – -3,99 €
0 2
FY2028 -3,24 €
-4,50 € – -1,74 €
0 7

Points Clés

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -88,42M
PEG of 0,24 suggests growth is underpriced

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-24,69%
ROIC-19,32%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
0,00
Current Ratio22,37
Interest Coverage0,00

Valorisation

P/E Ratio
-14,17
P/B Ratio3,17
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -105,43M
ROE -24,69% ROA -21,58%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -88,42M
ROIC -19,32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 22,37
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -14,17 P/B Ratio 3,17
P/S Ratio N/A PEG Ratio 0,24
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,49B Enterprise Value 1,45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -105,43M -83,72M -5,34M -9,93M -19,32M
EPS (Diluted) -2,31 -4,99 -4,44 -8,27 -16,68
Gross Profit -83 000,0 -27 000,0 -111 000,0 -114 000,0 -91 000,0
Operating Income -122,05M -88,12M -7,30M -9,84M -19,34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 488,62M 396,02M 37,86M 43,09M 54,92M
Total Liabilities 16,69M 13,80M 841 000,0 1,41M 3,88M
Shareholders' Equity 471,93M 382,22M 37,02M 41,67M 51,04M
Total Debt 1,93M 968 000,0 280 000,0 383 000,0 483 000,0
Cash & Equivalents 46,94M 61,58M 37,43M 42,45M 53,36M
Current Assets 343,86M 376,87M 37,59M 42,70M 54,42M
Current Liabilities 15,37M 13,04M 637 000,0 1,13M 3,50M